Loading
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
  • Log In
    • Register
Contacts us @ MediPr.org
Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong
  • MDnews
  • About [‘mediPr]
  • Search
  • Menu Menu

Non-Sponsored Content

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail


IMMUNO-THERAPY

AACR 2018: First-Line Nivolumab-Ipilimumab for TMB-High NSCLC

Medical writer: Stijn van den Borne, MSc | Last updated: 21st April 2018 | In: Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research

Article Keywords

AACR 2018, BMS, Bristol-Myers Squibb, carboplatin, cisplatin, CTLA4, gemcitabine, ipilimumab, nivolumab, non-squamous cell lung cancer, NSCLC, Oncology News, PD-1, PD-L1, pemetrexed, platinum-doublet, squamous cell lung cancer, TMB

First-line nivolumab (OpdivoⓇ) plus ipilimumab (YervoyⓇ) was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy for patients with tumour mutation burden (TMB)-high non-small cell lung cancer (NSCLC) in the Phase III CheckMate 227 trial. The results were presented during the 2018 AACR Annual Meeting with simultaneous online publication in the New England Journal of Medicine (NEJM).

“In this study of TMB-high non–small cell lung cancer, we found that nivolumab plus ipilimumab significantly improved progression-free survival compared to chemotherapy,”

~Matthew D. Hellman, MD, Memorial Sloan Kettering Cancer Center

Study Design

The CheckMate 227 (NCT02477826) initially was a multipart study comparing various immunotherapeutic regimens of programmed death 1 (PD-1) inhibitor nivolumab with chemotherapy (Figure 1). Eligible patients had Stage IV or recurrent NSCLC and not received prior systemic treatment. Participants were stratified as squamous NSCLC and non-squamous NSCLC. Subjects with insufficient tissue available for testing of PD-1 ligand (PD-L1) could not participate in the study.

Upon successful study-registration, participants were divided into a low PD-1 ligand (PD-L1) expression-group [PD-L1<1%] and high PD-L1 expression-group [PD-L1≥1%] and randomised to either nivolumab plus ipilimumab, chemotherapy alone, or nivolumab alone. Patients in the PD-L1<1% group and allocated to the nivolumab-arm received concomitant chemotherapy (Figure 1).

Based on the results of the CheckMate 012 and 032 studies, which showed efficacy of nivolumab plus ipilimumab in TMB-high lung cancer, the study was amended to include the co-primary progression-free survival endpoint comparing the immunooncology combination (IO-IO) with chemotherapy in patients with TMB-high (≥10 mutations per megabase [mut/Mb]).

AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer study design CheckMate 227 NCT02477826

Figure 1. Study design of the CheckMate 227 study. Platinum-doublet chemotherapy was subject to the histological subtype. Patients with non-squamous NSCLC received pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (area under the concentration-time curve [AUC] 5 or 6), every 3 weeks (q3w) for up to four cycles. Maintenance therapy with pemetrexed 500 mg/m2 after chemotherapy or with nivolumab 360 mg q3w plus pemetrexed 500 mg/m2 after nivolumab plus chemotherapy was optional. Patients with squamous NSCLC received gemcitabine (1000 or 1250 mg/m2) plus cisplatin (75 mg/m2), or gemcitabine (1000 mg/m2) plus carboplatin (AUC 5) q3w for up to four cycles.

Progression-Free Survival

In patients with TMB-high NSCLC the 1-year PFS rate was 43% for nivolumab plus ipilimumab compared with 13% for platinum-doublet chemotherapy (Figure 2). The median PFS was 7.2 months (nivolumab plus ipilimumab) versus 5.5 months (chemotherapy), a 42% risk reduction for disease progression or death (hazard ratio [HR]=0.58, P<0.001; 97.5%CI, 0.41-0.81).

1
2
3
4
AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer PFS CheckMate 227 NCT02477826
1

mPFS nivolumab plus ipilimumab: 7.2 months (95%CI, 5.5-13.2)

2

1-year PFS-rate nivolumab plus ipilimumab: 42.6%

3

mPFS chemotherapy: 5.5 months (95%CI, 4.4-5.8)

4

1-year PFS-rate chemotherapy: 13.2%

Figure 2. Progression-free survival (PFS) for chemotherapy vs ipilimumab plus nivolumab in TMB-high NSCLC, the co-primary endpoint of the CheckMate 227 study (NCT02477826). The combination IO-IO was associated with a 42% reduction of risk for disease progression or death (HR=0.58, P<0.001; 97.5% confidence interval [CI], 0.41-0.81). mPFS: median PFS.


Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

Newsletter

YOU MAY ALSO LIKE

the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant

The evolving role of NK1 in CINV management

https://medi-paper.com/wp-content/uploads/2021/04/the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant-e1618546071115.jpg 1024 1917 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2021-04-16 09:17:092021-04-20 13:49:08The evolving role of NK1 in CINV management
Lung Cancer Update April 2021

Lung Cancer Update April 2021

https://medi-paper.com/wp-content/uploads/2021/04/Lung-Cancer-Update-April-2021.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-04-08 16:28:082021-04-16 10:06:17Lung Cancer Update April 2021
Abemaciclib A review of the evidence through clinical case

Abemaciclib: A review of the evidence through clinical cases

https://medi-paper.com/wp-content/uploads/2021/03/Abemaciclib-A-review-of-the-evidence-through-clinical-case.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-03-25 15:09:132021-04-20 13:51:14Abemaciclib: A review of the evidence through clinical cases
The Role of Patient Blood Management for Inflammatory Bowel Disease-01

The Role of Patient Blood Management for Inflammatory Bowel Disease

https://medi-paper.com/wp-content/uploads/2021/02/The-Role-of-Patient-Blood-Management-for-Inflammatory-Bowel-Disease-01.png 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-27 19:09:322021-03-02 17:48:41The Role of Patient Blood Management for Inflammatory Bowel Disease
PreviousNext
the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant
16th April 2021

The evolving role of NK1 in CINV management

Lung Cancer Update April 2021
8th April 2021

Lung Cancer Update April 2021

Figure 3a. Response rates with nivolumab plus ipilimumab combination in TMB-high NSCLC.

    Figure 3b. Response rates with chemotherapy in TMB-high NSCLC.

    Objective Response Rate

    The nivolumab-ipilimumab combination showed an objective response rate (ORR) of 45.3%. Responses were durable, 68% had an ongoing response after 1 year. In the chemotherapy-arm, the ORR was 26.9% and 25% of responders had an ongoing response at 1 year.

    Figure 3a shows the response rates for nivolumab plus ipilimumab in TMB-high NSCLC and Figure 3b the response rates for chemotherapy in TMB-high NSCLC.

    Comparison with Overall Population

    In the overall population, ipilimumab plus nivolumab was associated with a higher 1-year PFS rate (30.9% vs 17.0%; HR=0.83; 95%CI, 0.72-0.96). However, the median PFS for IO-IO did not significantly differ from chemotherapy: 4.9 vs 5.5 months, respectively. In the subset of participants with TMB-low tumours (<10 mut/Mb), the median PFS was 3.2 months with the IO-IO vs 5.5 months with chemotherapy (HR=1.07; 95%CI, 0.84-1.35).

    Overall Survival

    At the time of database-lock on January 24, 2018, the overall survival (OS) data were not yet mature. Despite censoring of over 50% of the data points, the preliminary HR for OS in TMB-high patients was 0.79 (95%CI, 56-1.10) favouring the IO-IO combination over chemotherapy.

    Cross Over

    More than 24% of patients treated with IO-IO nivolumab plus ipilimumab for TMB-high NSCLC continued treatment at the time of database-lock, compared with 3.1% of chemotherapy-treated patients. Notably, 30% of CheckMate 227 patients on chemotherapy were treated with subsequent immunotherapy.

    Figure 3a. Response rates with nivolumab plus ipilimumab combination in TMB-high NSCLC.

      Figure 3b. Response rates with chemotherapy in TMB-high NSCLC.

      Figure 4a. CheckMate 227 TMB analysis as by the FoundationOne companion diagnostic (CDx).

          Figure 4b. CheckMate 227 PD-L1 level expression was evenly distributed across the TMB-high (PD-L1<1%: 21%; PD-L1≥1% 79%) and TMB-low groups (PD-L1<1%: 21%; PD-L1≥1% 79%), represented in this figure as total proportions.

          Biomarker Analysis

          A total of 1004 tissue samples were successfully tested for TMB-analysis by the FoundationOne companion diagnostic (CDx) (Figure 4a). In total, 444 (25.5%) samples of 1739 participants in the CheckMate 227 had ≥10 mut/Mb.

          PD-L1 level expression was independent of the TMB-classification and equally distributed across the two TMB subgroups. In the TMB-high subgroup, 21% of the samples tested for PD-L1 were found to have a <1% level expression, and 79% were found to have a PD-L1≥1% level expression. The distribution of PD-L1 <1% and ≥1% level expression was similar in the TMB-low group; 21% and 79%, respectively (Figure 4b).

          Subgroup analysis showed that nivolumab plus ipilimumab improved PFS among all patients regardless of PD-L1 expression or histologic (squamous vs non-squamous) subtypes. “This suggests TMB is an important independent biomarker,” commented the authors in the NEJM.

          Safety

          The safety of nivolumab plus ipilimumab was similar as reported in other trials of the IO-IO combination. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 31% of the nivolumab plus ipilimumab-treated patients. In this group, rash, diarrhoea, and anaemia (1.6% each) were the most frequently observed TRAEs. In the chemotherapy-arm, 36% of patients experienced grade 3/4 TRAEs. Treatment discontinuation due to TRAEs occurred more often in the IO-IO combination-group than in the chemotherapy-group: 12% vs 4.9%, respectively.

          References

          1. Hellmann MD et al. N Engl J Med. DOI: 10.1056/NEJMoa1801946.
          2. Hellmann MD et al. Abstract CT077. Presented at 2018 AACR Annual Meeting; April 14-18, 2018.

          Figure 4a. CheckMate 227 TMB analysis as by the FoundationOne companion diagnostic (CDx).

            Figure 4b. CheckMate 227 PD-L1 level expression was evenly distributed across the TMB-high (PD-L1<1%: 21%; PD-L1≥1% 79%) and TMB-low groups (PD-L1<1%: 21%; PD-L1≥1% 79%), represented in this figure as total proportions.

              Disclaimer

              This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

              © Copyright 2018 MediPaper Medical Communications Ltd. – AACR 2018: First-line Nivolumab-Ipilimumab in TMB-high NSCLC CheckMate 227 / NCT02477826.

              Share this entry
              • Share on Facebook
              • Share on Twitter
              • Share on WhatsApp
              • Share on Pinterest
              • Share on LinkedIn
              • Share by Mail

              YOU MAY ALSO LIKE

              the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant

              The evolving role of NK1 in CINV management

              https://medi-paper.com/wp-content/uploads/2021/04/the-evolving-role-of-nk1-in-cinv-management-chemotherapy-induced-nausea-vomiting-akynzeo-nepa-palonosetron-netupitant-e1618546071115.jpg 1024 1917 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2021-04-16 09:17:092021-04-20 13:49:08The evolving role of NK1 in CINV management
              Lung Cancer Update April 2021

              Lung Cancer Update April 2021

              https://medi-paper.com/wp-content/uploads/2021/04/Lung-Cancer-Update-April-2021.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-04-08 16:28:082021-04-16 10:06:17Lung Cancer Update April 2021
              Abemaciclib A review of the evidence through clinical case

              Abemaciclib: A review of the evidence through clinical cases

              https://medi-paper.com/wp-content/uploads/2021/03/Abemaciclib-A-review-of-the-evidence-through-clinical-case.jpg 1000 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-03-25 15:09:132021-04-20 13:51:14Abemaciclib: A review of the evidence through clinical cases
              The Role of Patient Blood Management for Inflammatory Bowel Disease-01

              The Role of Patient Blood Management for Inflammatory Bowel Disease

              https://medi-paper.com/wp-content/uploads/2021/02/The-Role-of-Patient-Blood-Management-for-Inflammatory-Bowel-Disease-01.png 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-27 19:09:322021-03-02 17:48:41The Role of Patient Blood Management for Inflammatory Bowel Disease
              Breast-Cancer-Update-2021

              Breast cancer update January 2021

              https://medi-paper.com/wp-content/uploads/2021/01/Breast-Cancer-Update-2021.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-01 16:44:392021-02-02 14:55:17Breast cancer update January 2021
              Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

              Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer

              https://medi-paper.com/wp-content/uploads/2021/01/Osimertinib-approved-as-the-first-adjuvant-treatment-for-early-non-small-cell-lung-cancer.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-01-28 11:43:032021-02-02 14:56:44Osimertinib approved as the first adjuvant treatment for early non-small cell lung cancer
              Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

              Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

              https://medi-paper.com/wp-content/uploads/2021/01/Increasing-dose-frequency-of-lanreotide-autogel-injections-in-neuroendocrine-tumours.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-01-27 11:18:282021-02-02 09:00:43Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours
              cabotegravir-and-rilpivirine-intramuscular-combination-safe-in-women

              Cabotegravir and rilpivirine intramuscular combination safe in women

              https://medi-paper.com/wp-content/uploads/2020/12/cabotegravir-and-rilpivirine-intramuscular-combination-safe-in-women.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 16:25:172021-03-02 17:51:19Cabotegravir and rilpivirine intramuscular combination safe in women
              hcv-infected-kidneys-safe-for-transplantation-with-antiviral-treatment

              HCV-infected kidneys safe for transplantation with antiviral treatment

              https://medi-paper.com/wp-content/uploads/2020/12/hcv-infected-kidneys-safe-for-transplantation-with-antiviral-treatment.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 15:46:392021-03-02 17:51:24HCV-infected kidneys safe for transplantation with antiviral treatment
              baloxavir-marboxil-recommended-as-post-exposure-prophylaxis-to-influenza-by-ema

              Baloxavir marboxil recommended as post-exposure prophylaxis to influenza by EMA

              https://medi-paper.com/wp-content/uploads/2020/12/baloxavir-marboxil-recommended-as-post-exposure-prophylaxis-to-influenza-by-ema.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-11 12:11:172021-03-02 17:51:13Baloxavir marboxil recommended as post-exposure prophylaxis to influenza by EMA
              U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

              US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

              https://medi-paper.com/wp-content/uploads/2017/08/U.S.-FDA-approved-immunecheckpoint-inhibitors--e1528903094981.jpg 1194 1254 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2020-12-08 18:00:012020-12-10 20:19:55US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020
              detecting metastases with psma pet in prostate cancer

              Detecting metastases with PSMA-PET in prostate cancer

              https://medi-paper.com/wp-content/uploads/2020/12/detecting-metastases-with-psma-pet-in-prostate-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-08 10:03:172020-12-11 15:12:41Detecting metastases with PSMA-PET in prostate cancer
              asco guidelines for the use of systemic therapies in advanced hepatocellular cancer

              ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer

              https://medi-paper.com/wp-content/uploads/2020/12/asco-guidelines-for-the-use-of-systemic-therapies-in-advanced-hepatocellular-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-07 17:20:022020-12-11 14:24:21ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer
              Sotorasib for the treatment of KRASG12C-mutated lung cancer

              Sotorasib for the treatment of KRASG12C mutated lung cancer

              https://medi-paper.com/wp-content/uploads/2020/10/Sotorasib-for-the-treatment-of-KRASG12C-mutated-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 10:16:382020-10-15 11:45:13Sotorasib for the treatment of KRASG12C mutated lung cancer
              Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

              Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

              https://medi-paper.com/wp-content/uploads/2020/10/Capmatinib-therapy-for-the-treatment-of-MET-positive-non-small-cell-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 09:46:042020-10-15 11:41:25Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer
              Selpercatinib-displays-efficacy-in-RET -fusion-positive-non-small-cell-lung-cancer

              Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

              https://medi-paper.com/wp-content/uploads/2020/09/Selpercatinib-displays-efficacy-in-RET-fusion-positive-non-small-cell-lung-cancer-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 21:04:252020-09-07 23:03:18Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

              First liquid biopsy for NSCLC to receive FDA approval

              https://medi-paper.com/wp-content/uploads/2020/09/First-liquid-biopsy-for-NSCLC-to-receive-FDA-approval-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 10:09:062020-09-08 09:56:03First liquid biopsy for NSCLC to receive FDA approval
              ESMO-releases-the-first-guideline-on-NGS-testing- in-cancers

              ESMO releases the first guideline on NGS testing in cancers

              https://medi-paper.com/wp-content/uploads/2020/09/ESMO-releases-the-first-guideline-on-NGS-testing-in-cancers-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 09:36:352020-09-08 08:52:38ESMO releases the first guideline on NGS testing in cancers
              residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance

              Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

              https://medi-paper.com/wp-content/uploads/2020/08/residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 16:18:002020-08-17 16:56:12Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance
              updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society

              Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

              https://medi-paper.com/wp-content/uploads/2020/08/updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 14:41:322020-08-25 14:37:07Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society
              Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat

              Lower-risk MDS patients benefit from novel drug, imetelstat

              https://medi-paper.com/wp-content/uploads/2020/07/Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat.jpg 844 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-07-10 17:24:512020-08-11 09:56:13Lower-risk MDS patients benefit from novel drug, imetelstat
              Carboplatin plus paclitaxel to be the new standard of care for anal cancer

              Carboplatin plus paclitaxel to be the new standard of care for anal cancer

              https://medi-paper.com/wp-content/uploads/2020/07/Carboplatin-plus-paclitaxel-to-be-the-new-standard-of-care-for-anal-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-07-10 17:24:482020-08-11 09:52:36Carboplatin plus paclitaxel to be the new standard of care for anal cancer
              ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

              ASCO 2020 Lung, Breast, and Liver Cancer Update

              https://medi-paper.com/wp-content/uploads/2020/06/ASCO-2020-ASCO20-virtual-meeting-NSCLC-SCLC-lung-cancer-breast-cancer-hepatocellular-cancer-HCC-colorectal-cancer-CRC-e1593749874717.jpg 794 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-06-30 09:37:482020-09-24 12:33:53ASCO 2020 Lung, Breast, and Liver Cancer Update
              Gastric Cancer ramucirumab cyramza pembrolizumab keytruda trastuzumab herceptin dMMR MSI HER2 VEGF VEGFR gastric adenocarcinoma GEJ gastroesophageal junction cancer

              Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

              https://medi-paper.com/wp-content/uploads/2020/04/gastric-adenocarcinoma-ramucirumab-cyramza-pembrolizumab-nivolumab-trastuzumab-dmmr-msi-her2-vegf-vegfr-gastric-cancer-gej-gastroesophageal-junction-cancer-pd-1-pd-l1-eli-lilly-lilly.png 850 1500 陳穎樂醫生 https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png 陳穎樂醫生2020-04-30 14:03:452021-03-02 17:50:45Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong
              Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

              Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

              https://medi-paper.com/wp-content/uploads/2020/02/Capivasertib-added-to-fulvestrant-improves-progression-free-survival-in-advanced-breast-cancer-patients.jpg 1000 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-02-19 23:37:222020-02-21 10:24:39Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients
              Capivasertib combined with paclitaxel improves survival of metastatic triple-negative breast cancer patients

              Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients

              https://medi-paper.com/wp-content/uploads/2019/12/Capivasertib-combined-with-paclitaxel-improves-survival-of-metastatic-triple-negative-breast-cancer-patients-e1582170747234.jpg 1000 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-02-11 17:30:382020-02-11 23:17:00Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients
              Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

              Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

              https://medi-paper.com/wp-content/uploads/2019/12/Olaparib-plus-Bevacizumab-as-Maintenance-Therapy-in-Ovarian-Cancer.jpg 844 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-01-24 16:32:552020-01-24 16:40:07Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer
              ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

              Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

              https://medi-paper.com/wp-content/uploads/2020/01/ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3-scaled.jpg 1056 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-01-12 23:33:152020-01-13 10:41:47Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer
              ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

              ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

              https://medi-paper.com/wp-content/uploads/2019/06/ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-.png 1000 750 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-06-12 14:12:322019-06-12 16:51:35ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised
              paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

              ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

              https://medi-paper.com/wp-content/uploads/2019/05/ASCO-2019-breast-cancer-TNBC-MBC-ABC-ASCO19-MONALEESA-7-TRINITI-1-FAKTION-TBCRC030-NeoSTOP-ETNA-GeparOLA-KRISTINE-PREDIX-CLEOPATRA-HERITAGE-SOPHIA-NALA-IMpassion-130-Tapur-Colet.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-06-03 16:53:572019-06-04 14:34:55ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

              Venetoclax FDA approved for CLL and SLL

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-15 16:19:292019-05-23 12:36:08Venetoclax FDA approved for CLL and SLL

              FDA approves avelumab plus axitinib for renal cell carcinoma

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-05-14 16:22:572019-05-22 22:49:14FDA approves avelumab plus axitinib for renal cell carcinoma

              Ramucirumab FDA approved for hepatocellular carcinoma

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-10 16:24:042019-05-23 11:58:38Ramucirumab FDA approved for hepatocellular carcinoma

              T-DM1 FDA approved for early breast cancer

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-03 16:24:342019-05-22 22:14:15T-DM1 FDA approved for early breast cancer

              Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-02 16:25:032019-05-22 22:14:36Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation
              Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

              Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

              https://medi-paper.com/wp-content/uploads/2019/04/Can-a-novel-temporary-and-fully-resorbable-surgical-implant-improve-the-outcome-of-common-hockey-and-soccer-injuries.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-26 20:05:262019-04-26 20:12:32Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

              Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-26 00:34:542019-04-26 00:38:58Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients
              KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

              KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

              https://medi-paper.com/wp-content/uploads/2019/04/KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancer.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-24 18:22:142019-04-24 18:22:14KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer
              Atezolizumab with or without cobimetinib vs regorafenib for previously treated metastatic colorectal cancer IMblaze370

              Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

              https://medi-paper.com/wp-content/uploads/2019/04/Atezolizumab-with-or-without-cobimetinib-vs-regorafenib-for-previously-treated-metastatic-colorectal-cancer-IMblaze370.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-22 21:21:372019-04-22 21:57:04Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

              Palbociclib approved for the treatment of male breast cancer 

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-22 16:13:232019-04-22 21:56:34Palbociclib approved for the treatment of male breast cancer 

              Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-22 14:35:132019-04-22 21:56:48Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

              Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-03-23 09:39:402019-03-23 09:41:21Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

              Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-03-09 23:15:272019-03-09 23:15:27Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer
              Immunoncology I-O drugs and immunotherapy for renal cancer RCC

              Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

              https://medi-paper.com/wp-content/uploads/2019/02/Immunoncology-I-O-drugs-and-immunotherapy-for-renal-cancer-RCC-.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-03-05 11:13:432019-03-07 14:27:09Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

              Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-02-23 15:05:352019-03-08 17:00:25Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

              Pembrolizumab FDA approved for adjuvant treatment of melanoma

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-02-16 14:55:172019-03-07 14:56:16Pembrolizumab FDA approved for adjuvant treatment of melanoma

              Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-01-21 23:16:452019-04-22 16:24:29Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

              Cabozantinib FDA approved in HCC patients failing sorafenib

              https://medi-paper.com/wp-content/uploads/2018/11/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-01-17 10:35:362019-02-18 13:23:29Cabozantinib FDA approved in HCC patients failing sorafenib
              Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

              Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

              https://medi-paper.com/wp-content/uploads/2019/01/Erasmus-University-MC-investigating-a-new-surgical-matrix-to-reduce-post-operative-complications.jpg 900 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-16 22:58:582019-01-16 23:09:21Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

              Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-14 15:36:172019-01-14 15:43:55Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

              Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-27 16:16:402018-12-27 16:16:40Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

              Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-27 15:51:482018-12-27 15:53:57Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)

              Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-22 16:54:192018-12-22 16:54:19Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

              Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-21 15:19:112018-12-21 15:32:40Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

              Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-11 13:21:272018-12-11 13:22:23Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC
              MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

              MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

              https://medi-paper.com/wp-content/uploads/2018/12/Depositphotos_159314198_xl-2015.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-05 22:00:342018-12-13 13:22:27MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab
              TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

              TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

              https://medi-paper.com/wp-content/uploads/2018/12/TIGR®Matrix-shows-promising-results-when-used-for-incisional-hernia-prevention-in-septic-patients-undergoing-laparoscopy.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-04 21:28:362018-12-05 11:50:08TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

              Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-29 15:08:432018-11-29 15:11:38Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

              TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-28 17:00:152018-11-28 18:03:05TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

              FDA Approves Truxima as Biosimilar to Rituxan

              https://medi-paper.com/wp-content/uploads/2018/11/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-28 14:34:182019-11-12 15:16:57FDA Approves Truxima as Biosimilar to Rituxan

              Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-23 23:17:102018-11-23 23:24:03Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

              Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-23 22:43:422018-11-23 22:43:42Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
              Robert Lewandowski Y90 TARE TheraSphere The Emerging Role of Yttrium90 in Primary and Metastatic Liver Cancer hepatocellular carcinoma hcc

              The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

              https://medi-paper.com/wp-content/uploads/2018/11/Y90-TARE-TheraSphere-The-Emerging-Role-of-Yttrium-90-in-Primary-and-Metastatic-Liver-Cancer..jpg 844 1500 Adrian YIP https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Adrian YIP2018-11-22 22:48:462018-12-11 10:42:29The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

              Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 23:38:102018-11-21 23:49:14Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

              Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas

              https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 23:01:122018-11-21 23:05:07Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas
              Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

              Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

              https://medi-paper.com/wp-content/uploads/2018/11/Fully-resorbable-synthetic-matrix-offers-improved-safety-for-breast-cancer-patients-undergoing-immediate-breast-reconstruction.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 16:41:202018-12-04 21:34:06Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

              Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

              https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-19 11:11:132018-11-19 13:45:58Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

              Lorlatinib FDA approved for metastatic ALK-positive NSCLC

              https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-06 11:30:052018-11-06 11:32:59Lorlatinib FDA approved for metastatic ALK-positive NSCLC
              ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

              ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

              https://medi-paper.com/wp-content/uploads/2018/10/esmo-2018-hcc-esmo18-liver-cancer-esmo-2018-hepatocellular-carcinoma-hepatobilliary-cholangiocarcinoma-btc-.png 1001 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-03 17:30:562018-11-05 12:51:54ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

              Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC

              https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-01 10:49:132018-11-01 10:53:51Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC
              Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

              Management of Immune-Mediated Hepatitis: a Case Report

              https://medi-paper.com/wp-content/uploads/2018/04/management-irAE-hepatitis-manage-immune-mediated-hepatitis-immunotherapy-I-O-immunooncology-immune-induced-hepatitis--e1542867473384.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-10-31 05:53:132018-11-22 15:01:08Management of Immune-Mediated Hepatitis: a Case Report

              PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer

              https://medi-paper.com/wp-content/uploads/2018/10/1539706020_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-18 20:50:302018-10-18 21:12:52PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer
              innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

              Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

              https://medi-paper.com/wp-content/uploads/2018/10/innovent-biologics-anti-pd1-sintilimab-plus-biosimilar-bevacizumab-receive-ind-status-by-china-nmpa-e1539612467836.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-15 22:26:302018-10-17 11:29:45Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA
              IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

              IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

              https://medi-paper.com/wp-content/uploads/2018/10/IMpower133-first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung-cancer-e1539272789598.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-11 23:48:162018-10-17 11:29:19IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
              Pembrolizumab plus chemotherapy effective in squamous NSCLC

              Pembrolizumab plus chemotherapy effective in squamous NSCLC

              https://medi-paper.com/wp-content/uploads/2018/10/Pembrolizumab-plus-chemotherapy-effective-in-squamous-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-08 00:43:132018-10-17 11:27:05Pembrolizumab plus chemotherapy effective in squamous NSCLC
              Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

              Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

              https://medi-paper.com/wp-content/uploads/2018/10/Ipilimumab-plus-nivolumab-for-persistent-or-recurrent-ovarian-cancer.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-07 00:13:112018-10-17 11:26:28Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer
              Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

              Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

              https://medi-paper.com/wp-content/uploads/2018/10/Brigatinib-prolongs-PFS-compared-to-crizotinib-in-ALK-Positive-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 17:27:422018-10-17 11:25:12Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC
              CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

              CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

              https://medi-paper.com/wp-content/uploads/2018/10/CAR-T-axicabtagene-ciloleucel-granted-Orphan-Drug-Designation-for-B-Cell-Lymphoma-by-the-Japan-MHLW.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 15:24:252018-10-17 11:23:17CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

              PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

              https://medi-paper.com/wp-content/uploads/2018/10/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-03 12:53:562018-10-17 11:20:52PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
              JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

              JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

              https://medi-paper.com/wp-content/uploads/2018/10/JAVELIN-Lung-200-avelumab-vs-docetaxel-in-patients-with-pretreated-advanced-non-small-cell-lung-cancer-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-02 01:01:252018-10-17 11:18:32JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

              Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC

              https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 23:18:162018-10-17 11:17:46Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC
              MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

              Duvelisib FDA approved for adult patients with R/R CLL or SLL

              https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 17:33:572018-09-25 17:46:01Duvelisib FDA approved for adult patients with R/R CLL or SLL
              MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

              Duvelisib FDA approved for adult patients with R/R follicular lymphoma

              https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 17:20:472018-09-25 17:36:29Duvelisib FDA approved for adult patients with R/R follicular lymphoma
              Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

              Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

              https://medi-paper.com/wp-content/uploads/2018/09/Front-line-atezolizumab-plus-chemotherapy-improves-PFS-in-NSCLC.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 10:01:562018-09-25 10:11:35Frontline atezolizumab plus chemotherapy improves PFS in NSCLC
              First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

              First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

              https://medi-paper.com/wp-content/uploads/2018/09/First-line-osimertinib-vs-EGFR-TKI-in-Asian-patients-with-advanced-NSCLC.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-24 13:24:282018-09-24 15:25:11First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC
              Early breast cancer treatment in China remains conservative

              Early breast cancer treatment in China remains conservative

              https://medi-paper.com/wp-content/uploads/2018/09/Early-breast-cancer-treatment-in-China-remains-conservative.jpg 1000 1510 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-23 23:35:002018-09-23 23:39:31Early breast cancer treatment in China remains conservative
              immuno-oncology I-O treatment for the irAE Rash©MediPaper Medical Communications Ltd

              ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash

              https://medi-paper.com/wp-content/uploads/2018/06/immuno-oncology-I-O-treatment-for-the-irAE-Rash.png 786 752 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-21 01:15:492018-09-21 13:29:44ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash
              Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

              Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

              https://medi-paper.com/wp-content/uploads/2018/02/Prof-Stefan-Kasper-on-I-O-in-EXTREME-ineligible-Head-and-Neck-Cancer-I-O-in-SCCHN-with-focus-on-EXTREME-ineligible-Patients-and-the-future-directions-of-combination-immunotherapy.jpg 924 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-19 12:54:212018-09-21 14:01:09Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN
              Camrelizumab anti-PD-1 with or without Chemotherapy for NPC

              Camrelizumab anti-PD-1 with or without chemotherapy for NPC

              https://medi-paper.com/wp-content/uploads/2018/09/Camrelizumab-anti-PD-1-with-or-without-Chemotherapy-for-NPC-e1537238880148.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-18 09:52:592018-09-18 09:55:32Camrelizumab anti-PD-1 with or without chemotherapy for NPC
              MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

              Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia

              https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-14 14:20:432018-09-14 14:20:43Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia
              Adrian TSE HKIOC irAE pneumonitis lung immunotherapy-induced pneumonitis I-O Immuno-Oncology cannonball metastases cancer©MediPaper Medical Communications Ltd

              I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis

              https://medi-paper.com/wp-content/uploads/2017/11/Adrian-TSE-HKIOC-irAE-pneumonitis-lung-immunotherapy-induced-pneumonitis-I-O-Immuno-Oncology-cannonball-metastases-cancer.jpg 838 798 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-14 13:13:492018-09-21 13:56:54I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis
              MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

              Venetoclax FDA label updated to include Minimal Residual Disease negativity data

              https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:26:092018-09-14 14:25:02Venetoclax FDA label updated to include Minimal Residual Disease negativity data
              Quizartinib Receives Orphan Drug Designation for FLT3-Mutated AML in Japan

              Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

              https://medi-paper.com/wp-content/uploads/2018/09/Quizartinib-Receives-Orphan-Drug-Designation-for-FLT3-Mutated-AML-in-Japan.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:21:342018-09-12 22:21:34Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan
              Lung Cancer Capmatinib plus gefitinib promising in MET-dysregulated NSCLC MediPaper Medical Communications Medical Writer Hong Kong 醫學寫作 醫學作家香港© Eraxion / 123RF Stock Photo

              Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

              https://medi-paper.com/wp-content/uploads/2018/09/Lung-Cancer-Capmatinib-plus-gefitinib-promising-in-MET-dysregulated-NSCLC-MediPaper-Medical-Communications-Medical-Writer-Hong-Kong-醫學寫作-醫學作家香港.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-11 21:33:342018-09-11 21:48:36Capmatinib plus gefitinib promising in MET-dysregulated NSCLC
              CAR-TCR Summit 2018 Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer© Royaltystockphoto / 123RF Stock Photo

              CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

              https://medi-paper.com/wp-content/uploads/2018/09/CAR-TCR-Summit-2018-Preliminary-first-in-human-data-with-CAR-Claudin18.2-T-in-gastric-and-pancreatic-cancer.jpg 1054 1505 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-09 09:38:282018-09-09 09:38:28CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer
              DRIVER connects cancer patients in China and the United States to the best care© Kentoh / 123RF Stock Photo

              DRIVER connects cancer patients in China and the United States to the best care

              https://medi-paper.com/wp-content/uploads/2018/09/DRIVER-connects-cancer-patients-in-China-and-the-United-States-to-the-best-care.jpg 994 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-07 21:45:362018-09-07 21:45:36DRIVER connects cancer patients in China and the United States to the best care
              Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

              Plasma TMB predicts response to atezolizumab in NSCLC patients

              https://medi-paper.com/wp-content/uploads/2018/08/Blood-based-TMB-assay-predicts-response-to-atezolizumab-in-NSCLC-patients.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-31 07:42:492018-08-31 14:33:03Plasma TMB predicts response to atezolizumab in NSCLC patients
              First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation© luchschen / 123RF Stock Photo

              First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

              https://medi-paper.com/wp-content/uploads/2018/08/First-in-Class-Oncology-Vaccine-BIL06v-Starts-Phase-1-Evaluation.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-22 11:48:172018-08-27 09:35:59First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation
              Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)© FDA

              Pembrolizumab and atezolizumab USPIs updated by FDA

              https://medi-paper.com/wp-content/uploads/2018/08/fda-e1537925353881.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 12:10:412018-08-21 13:18:15Pembrolizumab and atezolizumab USPIs updated by FDA
              Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)© FDA

              Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

              https://medi-paper.com/wp-content/uploads/2018/08/fda-e1537925353881.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 11:24:202018-08-23 10:48:02Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)
              Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

              Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

              https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lenvatinib-capsules-Lenvima-Eisai-Inc.-for-1st-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-HCC.-More-Information-.-August-16-2018-e1537925351885.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 10:34:252018-08-21 11:37:56Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC
              Talazoparib in advanced breast cancer patients with a germline BRCA1:2 mutation

              Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

              https://medi-paper.com/wp-content/uploads/2018/08/Talazoparib-in-advanced-breast-cancer-patients-with-a-germline-BRCA12-mutation.jpg 687 1030 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-19 01:07:502018-08-21 21:55:19Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation
              CheckMate 032 Nivolumab ipilimumab metastatic esophagogastric cancer

              CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer

              https://medi-paper.com/wp-content/uploads/2018/08/CheckMate-032-Nivolumab-ipilimumab-metastatic-esophagogastric-cancer.jpg 667 1000 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-18 23:22:562018-08-19 01:08:26CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer
              Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

              Lenvatinib FDA approved for 1st-line treatment of HCC

              https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lenvatinib-capsules-Lenvima-Eisai-Inc.-for-1st-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-HCC.-More-Information-.-August-16-2018-e1537925351885.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-18 15:50:342018-08-21 22:35:40Lenvatinib FDA approved for 1st-line treatment of HCC
              Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China©Alex011973 / 123RF Stock Photo

              Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

              https://medi-paper.com/wp-content/uploads/2018/08/Pan-EGFR-TKI-pirotinib-has-commenced-into-Phase-II-clinical-testing-in-China.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-13 23:09:022018-09-07 21:59:21Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China
              FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

              FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL

              https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-09 00:58:382018-08-12 12:28:54FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL
              FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

              Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients

              https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-01 09:21:032018-08-12 16:46:52Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-31 15:44:032018-07-31 15:45:41Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours
              T790M osimertinib nsclc brain metastasis CNS metastases Osimertinib in patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer and brain metastases AURA3© srr283/123RF

              Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

              https://medi-paper.com/wp-content/uploads/2018/08/T790M-osimertinib-nsclc-CNS-brain-metastasis-Osimertinib-in-patients-With-T790M-Positive-Advanced-Non-Small-Cell-Lung-Cancer-and-brain-metastases-AURA3.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-30 23:43:262018-08-20 12:36:41Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)
              Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

              Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

              https://medi-paper.com/wp-content/uploads/2018/08/Anti-PD1-with-Cemiplimab-in-Advanced-Cutaneous-Squamous-Cell-Carcinoma.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-26 23:44:412018-08-22 23:58:36Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-23 11:33:402018-07-30 10:43:08Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia
              FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018

              Filgrastim-aafi FDA approved as Filgrastim Biosimilar

              https://medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-20 10:58:232018-08-11 23:55:01Filgrastim-aafi FDA approved as Filgrastim Biosimilar
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Ribociclib FDA label updated to include pre- and perimenopausal women

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-19 01:01:572018-07-30 10:42:22Ribociclib FDA label updated to include pre- and perimenopausal women
              FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018

              Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)

              https://medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-17 10:14:112018-07-30 10:42:09Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)
              EBV pembrolizumab gastric cancer - MSI-H pembrolizumab gastric cancer - CPS pembrolizumab gastric cancer - MSI, EBV, CPS predict pembrolizumab outcome in gastric cancer© abhijith3747/123RF

              EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer

              https://medi-paper.com/wp-content/uploads/2018/08/EBV-pembrolizumab-gastric-cancer-MSI-H-pembrolizumab-gastric-cancer-CPS-pembrolizumab-gastric-cancer-MSI-EBV-CPS-predict-pembrolizumab-outcome-in-gastric-cancer.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-16 14:03:432018-08-31 08:15:52EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-11 20:52:132018-07-30 10:41:58Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-02 22:14:052018-07-30 10:41:23Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved
              ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower©eraxion / 123RF Stock Photo

              ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

              https://medi-paper.com/wp-content/uploads/2018/06/ASCO-2018-nsclc-immunotherapy-ASCO18-lung-cancer-pembrolizumab-avelumab-nivolumab-duravalumab-ipilimumab-osimertinib-dacomitinib-lorlatinib-crizotinib-alectinib-keytruda-KEYNOTE-CheckMate-JAVELIN-IMpower.jpg 1000 1500 Anne John Michael https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anne John Michael2018-06-25 18:22:252018-08-21 11:43:54ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised
              FDA  has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.  More Information.  June 19, 2018

              FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

              https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-19 14:01:322018-07-30 10:40:51FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma
              ASCO 2018 breast cancer TNBC MBC ABC ASCO18 PHEREXA D-CARE ABCSG-18 ASTRRA TEXT SOFT MONARCH-2 MONALEESA-3 SANDPIPER BOLERO-6 TOPACIO KEYNOTE-162 TONIC TOPACIO GeparNeuvo©eraxion / 123RF Stock Photo

              ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

              https://medi-paper.com/wp-content/uploads/2018/06/ASCO-2018-breast-cancer-TNBC-MBC-ABC-ASCO18-PHEREXA-D-CARE-ABCSG-18-ASTRRA-TEXT-SOFT-MONARCH-2-MONALEESA-3-SANDPIPER-BOLERO-6-TOPACIO-KEYNOTE-162-TONIC-TOPACIO-GeparNeuvo.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-06-19 09:02:512018-06-19 23:57:08ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-14 22:56:042018-07-30 10:40:22Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-14 22:42:142018-07-30 10:40:10FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-13 21:59:012018-07-30 10:39:54FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 
              ASCO18 ASCO 2018 HCC hepatocellular carcinoma liver cancer pembrolizumab KEYTRUDA atezolizumab TECENTRIQ PD-1 PD-L1 immunecheckpoint immunotherapy ramucirumab cabozantinib KEYNOTE-224 SCRUM-Japan GI-SCREEN CELESTIAL REACH-2© krishnacreations / 123RF Stock Photo

              ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

              https://medi-paper.com/wp-content/uploads/2018/06/ASCO18-ASCO-2018-HCC-hepatocellular-carcinoma-liver-cancer-pembrolizumab-KEYTRUDA-atezolizumab-TECENTRIQ-PD-1-PD-L1-immunecheckpoint-immunotherapy-ramucirumab-cabozantinib-KEYNOTE-224-SCRUM-Japan-GI-SCREEN-CELESTIAL-REACH-2.jpg 1000 1500 Anne John Michael https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anne John Michael2018-06-10 11:59:542018-08-23 10:33:26ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              FDA approves venetoclax in 2nd-line for patients with CLL or SLL

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-09 11:25:082018-09-25 17:51:30FDA approves venetoclax in 2nd-line for patients with CLL or SLL
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-06 16:07:462018-08-11 23:55:46FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy
              IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclcbravajulia / 123RF Stock Photo

              AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

              https://medi-paper.com/wp-content/uploads/2018/05/IMPower150-Reck-Socinski-ELCC-AACR-2018-firstline-atezolizumab-bevacizumab-chemotherapy-non-squamous-nsclc.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-05-10 16:19:462018-05-24 09:31:31AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC
              US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel

              US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018

              https://medi-paper.com/wp-content/uploads/2018/04/US-FDA-approved-CAR-t-cell-BiTE-DAR-T-cell-CD19-Immunotherapies-blinatumomab-axicabtagene-ciloleucel-tisagenlecleucel.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-05-02 10:00:352018-05-24 09:36:21US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-30 13:35:562018-07-30 11:42:21Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-19 13:36:062018-07-30 11:15:04FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)
              NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhikrishnacreations / 123RF Stock Photo

              Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

              https://medi-paper.com/wp-content/uploads/2018/04/NCT02578680-Keynote189-pembrolizumab-chemotherapy-nsclc-NEJM-Leena-Gandhi.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-19 01:27:262018-05-24 09:37:16Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-16 13:59:012018-07-30 11:50:31Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC
              Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

              Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

              https://medi-paper.com/wp-content/uploads/2018/04/Keynote-042-Keynote-024-pembrolizumab-nsclc-keytruda-nsclc-non-squamous-squamous-PD-L1-expression-1-20-50-Tony-Mok-MD-NCT02220894-Pembrolizumab-effective-in-frontline-NSCLC-with-low-PD-L1-expression.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-10 20:15:112018-05-24 09:37:32Pembrolizumab effective in frontline NSCLC with low PD-L1 expression
              Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

              Everolimus suspension approved in TSC-associated partial-onset seizures

              https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-10 14:07:302018-07-30 14:22:09Everolimus suspension approved in TSC-associated partial-onset seizures
              Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

              I-O in Special Populations: Diabetes and Concomitant Steroids

              https://medi-paper.com/wp-content/uploads/2018/02/Herbert-Loong-on-irAEs-Immunotherapy-I-O-and-New-Onset-Diabetes-or-immune-mediated-diabetes.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-06 09:00:412018-08-11 23:56:01I-O in Special Populations: Diabetes and Concomitant Steroids
              Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

              Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

              https://medi-paper.com/wp-content/uploads/2018/04/Crizotinib-beneficial-for-East-Asian-NSCLC-patients-with-ROS1-alterations-crizotinib-asian-crizotinib-ros1-crizotinib-asian-nsclc-patients-crizotinib-asian-non-small-cell-lung-cancer-patients-e1522913753323.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-04 16:00:112018-04-19 13:57:57Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

              Death due to cancer on the decline for most tumours in Europe

              https://medi-paper.com/wp-content/uploads/2018/03/1522336566_Oncology-Breast-CNS-Chemotherapy-Endocrine-GI-GU-Geriatric-Gynecologic-GYN-OB-Head-and-Neck-Haematology-Immunotherapy-Lung-Melanoma-Skin-NET-Paediatric-Pathology-Sarcoma-Surgery-Targeted-Therapy-Translational-03.jpg 277 450 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-31 11:03:502018-08-10 11:57:59Death due to cancer on the decline for most tumours in Europe
              immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

              Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)

              https://medi-paper.com/wp-content/uploads/2018/03/nivolumab-npc-opdivo-nasopharyngeal-carcinoma-brigette-ma-CUHK-phase-II-nci-9742-study-JCO-journal-of-clinical-oncology.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-31 09:20:312018-05-24 09:38:41Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)
              ©aquir / 123RF Stock Photo

              FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

              https://medi-paper.com/wp-content/uploads/2018/05/1526019694_US-FDA-Oncology-Haematology-Drug-Approvals-e1537929700820.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-03-29 14:21:342018-09-25 17:51:10FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%
              Making sense of immunotherapy in NSCLC

              Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

              https://medi-paper.com/wp-content/uploads/2018/03/Making-sense-of-immunotherapy-in-NSCLC.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-26 16:06:282018-07-31 23:06:54Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)
              manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

              Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

              https://medi-paper.com/wp-content/uploads/2017/11/image.png 852 1471 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-29 22:12:232018-04-19 10:46:51Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects
              2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

              Do you know your lifetime risk on Pancreatic Cancer?

              https://medi-paper.com/wp-content/uploads/2016/11/2016-Pancreatic-Cancer-medipaper-medical-communications-medical-writer-hire-healthcare-writers-hong-kong.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-20 12:29:422018-02-09 14:08:00Do you know your lifetime risk on Pancreatic Cancer?
              HKBCF luminal breast cancer can cdk46 inhibition by palbociclib improve on chemotherapy medipaper medical writer hong kong

              Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

              https://medi-paper.com/wp-content/uploads/2017/10/HKBCF-luminal-breast-cancer-can-cdk46-inhibition-by-palbociclib-improve-on-chemotherapy-medipaper-medical-writer-hong-kong.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-10-25 22:58:382018-02-09 14:08:00Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?
              us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

              Pembrolizumab approved for advanced gastric cancer

              https://medi-paper.com/wp-content/uploads/2018/07/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925322207.jpg 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-22 23:33:522018-07-26 15:04:47Pembrolizumab approved for advanced gastric cancer
              us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

              Nivolumab approved for sorafenib-refractory HCC

              https://medi-paper.com/wp-content/uploads/2018/07/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925322207.jpg 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-22 23:21:412018-07-26 11:42:35Nivolumab approved for sorafenib-refractory HCC
              Nivolumab Renal Cell Cancer Symposium Highlight

              Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

              https://medi-paper.com/wp-content/uploads/2017/09/Nivolumab-Renal-Cell-Cancer-Symposium-Highlight.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-19 23:04:512018-08-11 23:56:17Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy
              adjuvant hormonal therapy

              Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

              https://medi-paper.com/wp-content/uploads/2017/08/adjuvant-hormonal-therapy.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-07-05 22:46:312018-02-09 14:08:00Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?
              2017 CICS immunooncology annual meeting oncology medical writer medipaper medical communications

              Interested in Attending an Immunooncology Conference?

              https://medi-paper.com/wp-content/uploads/2017/02/2017-CICS-immunooncology-annual-meeting-oncology-medical-writer-medipaper-medical-communications.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-06-21 16:05:482018-02-09 14:08:00Interested in Attending an Immunooncology Conference?
              esmo 2016 breast cancer ribociclib palbociclib abemaciclib data medipaper medicall writer

              ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

              https://medi-paper.com/wp-content/uploads/2016/10/ESMO-2016-Breast-Cancer-Palbociclib-Ribociclib-Abemaciclib-data-MediPaper-Medical-Writer-e1478671413852.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-11-09 16:00:442018-05-11 17:14:06ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data
              PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

              PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

              https://medi-paper.com/wp-content/uploads/2016/08/PD-L1-Biomarker-for-Response-DAKO-22C3-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-26 14:00:352018-05-11 17:21:18PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data
              Biomarkers Ipilimumab Treatment MediPaper Medical Communications

              Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

              https://medi-paper.com/wp-content/uploads/2016/10/Biomarkers-Ipilimumab-Treatment-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-24 10:12:072018-05-11 17:18:58Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies
              ESMO 2016 ipilimumab data medipaper medical communications

              ESMO16 Ipilimumab data – Download the PPT

              https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-ipilimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-11 11:10:102018-05-11 17:28:19ESMO16 Ipilimumab data – Download the PPT
              ESMO 2016 pembrolizumab data medipaper medical communications

              ESMO16 Pembrolizumab data – Download the PPT

              https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-pembrolizumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-10 21:08:122018-05-11 17:28:28ESMO16 Pembrolizumab data – Download the PPT
              ESMO 2016 durvalumab avelumab tremelimumab data medipaper medical communications

              ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT

              https://medi-paper.com/wp-content/uploads/2016/10/ESMO-2016-durvalumab-avelumab-tremelimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-10 10:30:512018-05-11 17:28:38ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT
              ESMO 2016 atezolizumab data medipaper medical communications

              ESMO16 Atezolizumab data – Download the PPT

              https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-atezolizumab-data-medipaper.jpg 665 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-09 17:50:232018-05-11 17:28:52ESMO16 Atezolizumab data – Download the PPT
              ESMO 2016 nivolumab data medipaper medical communications

              ESMO16 Nivolumab data – Download the PPT

              https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-nivolumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-09 16:30:582018-05-11 17:29:00ESMO16 Nivolumab data – Download the PPT
              cancer awareness improves outcome medipaper medical communications

              Cancer symptom awareness linked to survival

              https://medi-paper.com/wp-content/uploads/2016/09/cancer-awareness-improves-outcome-medipaper-medical-communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-30 21:33:432018-02-09 13:51:10Cancer symptom awareness linked to survival
              2016 ASCO ovarian cancer guidelines neo-adjuvant chemotherapy medipaper medical communications

              ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

              https://medi-paper.com/wp-content/uploads/2016/09/2016-asco-ovarian-cancer-guidelines-neo-adjuvant-chemotherapy-medipaper-medical-communications-e1478394814429.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-27 21:53:422018-02-09 14:07:58ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated
              IMM-101 plus gemcitabine-medipaper medical communications BW

              IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer

              https://medi-paper.com/wp-content/uploads/2016/09/IMM-101-plus-gemcitabine-medipaper-medical-communications_medical_writer_hong_kong.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-25 00:19:582018-02-09 13:51:09IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer
              palbociclib-first-in-class

              Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor

              https://medi-paper.com/wp-content/uploads/2016/04/palbociclib-first-in-class.jpg 662 1095 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-17 00:46:162018-05-11 17:13:52Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor
              Ki67 breast cancer medical writer epotomics

              Ki67 in Breast Cancer: an overview

              https://medi-paper.com/wp-content/uploads/2016/04/Ki67-breast-cancer-medical-writer-epotomics-com.png 998 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-06 00:07:072018-05-11 17:15:08Ki67 in Breast Cancer: an overview
              ASCO 2016 ribociclib & abemaciclib Data - MediPaper Medical Communications

              ASCO16 Ribociclib & Abemaciclib Data

              https://medi-paper.com/wp-content/uploads/2016/06/ribociclib-abemaciclib-ASCO2016-Data-MediPaper-Medical-Communications.jpg 1033 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-05 23:30:482018-05-11 17:17:01ASCO16 Ribociclib & Abemaciclib Data
              ASCO 2016 Palbociclib Data MediPaper Medical Communications

              ASCO16 palbociclib (Ibrance©) Data

              https://medi-paper.com/wp-content/uploads/2016/06/ASCO-2016-Palbociclib-Data-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-04 22:51:302018-05-11 17:16:17ASCO16 palbociclib (Ibrance©) Data
              ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

              ASCO16 Avelumab, Durvalumab, and Tremelimumab

              https://medi-paper.com/wp-content/uploads/2016/06/ASCO-2016-Azelumab-Durvalumab-and-Tremelimumab-Data.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-03 11:57:432018-05-11 17:25:17ASCO16 Avelumab, Durvalumab, and Tremelimumab
              asco 2016 atezolizumab data

              ASCO16 Atezolizumab (Tecentriq©) Data

              https://medi-paper.com/wp-content/uploads/2016/06/asco-2016-atezolizumab-data.jpg 1024 1536 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-02 15:15:132018-05-11 17:25:04ASCO16 Atezolizumab (Tecentriq©) Data
              ASCO2016 ipilimumab data - MediPaper Medical Communications

              ASCO16 Ipilimumab (Yervoy©) Data

              https://medi-paper.com/wp-content/uploads/2016/05/ASCO2016-ipilimumab-data-MediPaper-Medical-Communications.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-31 13:05:442018-05-11 17:22:00ASCO16 Ipilimumab (Yervoy©) Data
              asco 2016 nivolumab medipaper medical communications

              ASCO16 Nivolumab (Opdivo©) Data

              https://medi-paper.com/wp-content/uploads/2016/05/asco-2016-nivolumab.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:44:422018-05-11 17:25:59ASCO16 Nivolumab (Opdivo©) Data
              asco 2016 pembrolizumab medipaper medical communications

              ASCO16 Pembrolizumab (Keytruda©) Data

              https://medi-paper.com/wp-content/uploads/2016/05/asco-2016-pembrolizumab.jpg 851 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:23:322018-05-11 17:22:45ASCO16 Pembrolizumab (Keytruda©) Data
              PreviousNext
              6 replies

              Trackbacks & Pingbacks

              1. Addition of a CTLA-4–Targeted Therapy to a Checkpoint Inhibitor in Ovarian Cancer | MediPaper says:
                7th October 2018 at 12:13 AM

                […] Copyright 2018 MediPaper Medical Communications Ltd. – Ipilimumab plus nivolumab for persistent or recurrent ovarian […]

                Log in to Reply
              2. Plasma-TMB predicts response to atezolizumab in NSCLC patients says:
                31st August 2018 at 12:30 PM

                […] multiple studies have linked a high-TMB to improved outcomes with immune-checkpoint inhibitors. A less invasive diagnostic method, such as […]

                Log in to Reply
              3. Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC) says:
                31st July 2018 at 11:04 PM

                […] results of the Phase III CheckMate 227 show that the combination of nivolumab and ipilimumab improves PFS when compared with chemotherapy […]

                Log in to Reply
              4. ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised says:
                25th June 2018 at 10:30 PM

                […] meeting. This year, encouraging results with combinations therapies were presented, including CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 […]

                Log in to Reply
              5. Approved Immune-Checkpoint Inhibitors and Immunotherapies per 23-APR-2018 says:
                1st June 2018 at 4:49 PM

                […] /wp-content/uploads/2018/04/US-FDA-approved-CAR-t-cell-BiTE-DAR-T-cell-CD19-Immunotherapies-blinatumomab-axicabtagene-ciloleucel-tisagenlecleucel.jpg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.png Stijn van den Borne, MSc2018-05-02 10:00:352018-05-24 09:36:21US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018Hywards / 123RF Stock Photo […]

                Log in to Reply
              6. First-line Nivolumab-Ipilimumab in TMB-high NSCLC - MediNews Asia says:
                24th May 2018 at 12:16 AM

                First-line nivolumab (OpdivoⓇ) plus ipilimumab (YervoyⓇ) was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy for patients with tumour mutation burden (TMB)-high non-small cell lung cancer (NSCLC) in the Phase III CheckMate 227 trial. The results were presented during the 2018 AACR Annual Meeting with simultaneous online publication in the New England Journal of Medicine (NEJM).

                Log in to Reply

              Leave a Reply

              Want to join the discussion?
              Feel free to contribute!

              Leave a Reply Cancel reply

              You must be logged in to post a comment.

              © Copyright 2018 MediPaper Medical Communications Ltd. – AACR 2018: First-line Nivolumab-Ipilimumab in TMB-high NSCLC CheckMate 227 / NCT02477826.

              Therapeutic Areas

              Login

              or
              Login with Google
              Login with Facebook
              Login with Twitter
              Login with LinkedIn
              • Register
              • Lost your password?

              Or, sign up for our newsletter


               MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | Medical Writer Jobs | PMHub
              © 2016-2021 MediPaper Medical Communications Ltd. | Website by [’mediPr] | 醫學作家香港 | Privacy Policy | Cookie Policy
              • Facebook
              • LinkedIn
              • Twitter
              • Instagram
              • Pinterest
              • Youtube
              • Mail
              • Rss
              FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon... Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K me...
              Scroll to top

              This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

              OKPrivacy Settings

              Cookies and Privacy on medi-paper.com



              Cookie Policy

              How MediPaper uses cookies is explained in our Cookie Policy

              Privacy Policy

              Read MediPaper's Privacy Policy

              Google Analytics cookies

              These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

              If you do not want that we track your visist to our site you can disable tracking in your browser here:

              Other external services

              We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

              Google Webfont Settings:

              Google Map Settings:

              Vimeo and Youtube video embeds:

              Accept settingsHide notification only
              Copy link
              CopyCopied
              Powered by Social Snap
              MediPaper Medical Communications Agency Hong Kong Blog